Bernard H. Munos is the founder of the InnoThink Center for Research in Biomedical Innovation, a consultancy that focuses on pharmaceutical innovation — specifically, where it comes from and how to get more of it. He previously served as an advisor for corporate strategy at Eli Lilly and Company, where he focused on disruptive innovation and the radical redesign of research and development.

Several of Munos’ research papers — published in Nature and Science — have helped stimulate a broad rethinking of the pharmaceutical business model by industry, investors, policymakers, regulators and patient advocates. His work has been profiled by Forbes magazine, and the popular industry publication FiercePharma has named him one of the 25 most influential people in biopharma. Munos has presented his findings to the National Academies, the Institute of Medicine, the President’s Cancer Panel, the National Institutes of Health Leadership Forum, the World Health Organization, the OECD, the Kauffman Foundation, the U.S. Patent and Trademark Office, the Council for American Medical Innovation, and many others.

Munos received his MBA from Stanford University and holds graduate degrees in agricultural economics and animal science from the University of California, Davis, and the Paris Institute of Technology for Life, Food and Environmental Sciences. He serves on the Advisory Council and the Cures Acceleration Network Review Board of NIH’s National Center for Advancing Translational Sciences (NCATS), and is a member of the Institute of Medicine’s Forum on Drug R&D and Translation. He is also an Advisor to the journal *Science Translational Medicine*, a non-executive Director for Glenmark Pharmaceuticals, and he advises companies, non-profit and government-funded research organizations on how to become better innovators.